Cancer Network

05/31/2026

Regular physical activity was noted to decrease cardiovascular risk among patients with breast cancer.

05/31/2026

🫁 Taletrectinib improved quality of life among patients with advanced ROS1-positive NSCLC!

Patient-reported outcomes from the phase 2 TRUST-II trial provide further support for the use of taletrectinib in this patient population.

American Society of Clinical Oncology

05/31/2026

ctDNA dynamics after 3 months of adjuvant chemo provided identified patient populations who benefit from extended treatment duration in resected stage I to IV CRC.

https://hubs.li/Q04jvZS20

Serial ctDNA assessment after 3 months of adjuvant chemotherapy stratified recurrence risk and identified which patients with resected CRC benefit from extended treatment.

05/31/2026

Concurrent GLP-1 receptor agonists with ICI treatment may be associated with improved long-term survival among patients with cancer.

https://hubs.li/Q04jvSXg0

A large real-world analysis found that concurrent GLP-1 receptor agonist use was linked to significantly improved long-term survival and lower rates of irAEs in patients receiving ICIs.

05/31/2026

Three years of adjuvant low-dose aspirin did not improve DFS vs placebo in patients with stage III CRC receiving standard adjuvant chemotherapy.

https://hubs.li/Q04js6HF0

Adjuvant aspirin did not improve disease-free survival vs placebo in patients with stage III colorectal cancer who received standard adjuvant chemotherapy.

05/31/2026

Carboplatin-based induction-concurrent CRT showed noninferior efficacy vs cisplatin-based treatment in patients with locally advanced nasopharyngeal carcinoma.

https://hubs.li/Q04jtsnP0

Efficacy with carboplatin-based induction-concurrent chemotherapy was noninferior to cisplatin, representing a viable alternative for patients with LA-NPC.

05/31/2026

RP1 plus nivolumab yielded deep and durable responses in advanced melanoma after progression on anti-PD-1 therapy in the 3-year survival analysis of the phase 3 IGNYTE trial.

https://hubs.li/Q04jqtHs0

An OS of 32.9 months was noted with RP1 plus nivolumab for patients who had progressed on prior anti-PD-1 therapy with advanced melanoma.

05/31/2026

The phase 3 RAMPART trial did not show a DFS benefit with durvalumab monotherapy vs SOC active monitoring in resected RCC at intermediate- or high-risk of recurrence.

https://hubs.li/Q04jvNSc0

RAMPART finds durvalumab after kidney cancer surgery cuts recurrence risk but misses DFS significance; combo therapy shines in highest-risk patients.

05/31/2026

A personalized neoantigen vaccine plus an anti-PD-1 was feasible, safe, and generated durable anti-tumor immune responses in patients with newly diagnosed glioblastoma.

https://hubs.li/Q04jvg4J0

A personalized neoantigen vaccine plus an anti-PD-1 was feasible, safe, and generated durable anti-tumor immune responses in newly diagnosed glioblastoma.

05/31/2026

Data from the phase 3 LIBRETTO-432 study may support adjuvant selpercatinib as a new standard of care in this NSCLC population.

https://hubs.li/Q04jvwRY0

Data from the phase 3 LIBRETTO-432 study may support adjuvant selpercatinib as a new standard of care in this NSCLC population.